A case of lamivudine-sensitive de novo acute hepatitis B induced by rituximab with the CHOP regimen for diffuse large B cell lymphoma

Hepatology International

Volumn 3, Issue 1, 2009, Pages 316-322

  Takahashi, Toru ^a   Koike, Tadashi ^a   Hashimoto, Shigeo ^a   Miura, Tomofumi ^a   Nakamura, Junichiro ^a   Yamada, Satoshi ^a   Miura, Tsutomu ^a   Yanagi, Masahiko ^a   Yamazaki, Kazuhide ^b   Okoshi, Shogo ^b   Aoyagi, Yutaka ^b  

^a NAGAOKA RED CROSS HOSPITAL   (Japan)

^b NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

De novo acute hepatitis B; Lamivudine; Rituximab

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CD20 ANTIGEN; CD3 ANTIGEN; CD38 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; PREDNISOLONE; RITUXIMAB; VINCRISTINE; VIRUS DNA;

ADULT; ANOREXIA; ARTICLE; B CELL LYMPHOMA; CASE REPORT; CELL INFILTRATION; COMPUTER ASSISTED TOMOGRAPHY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG WITHDRAWAL; ERYTHROPENIA; FEMALE; GIANT CELL; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JAUNDICE; LABORATORY TEST; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER BIOPSY; LIVER INJURY; LIVER PARENCHYMA; LYMPHADENOPATHY; MALAISE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TONSILLITIS; TOXIC HEPATITIS; VIRUS LOAD; VIRUS REACTIVATION;

EID: 59749085661     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-008-9094-x     Document Type: Article

References (29)

1. Millman I, London WT, Blumberg BS. Immunofluorescent identification of Australian antigen. N Engl J Med 1973;288:108-109.
2. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med 2004;350:1118-1129. doi: 10.1056/ NEJMra031087.
3. Lee W. Hepatitis B infection. N Engl J Med 1997;337:1735-1745. doi: 10.1056/NEJM199712113372406.
4. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med 2001;344:68-69. doi: 10.1056/NEJM200101043440120.
5. Ng HJ, Lim LC. Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: Case report. Ann Hematol 2001;80:549-552. doi: 10.1007/s002770100346.
6. Skrabs C, Müller C, Agis H, Mannhalter C, Jäger U. Treatment of HBV-carrying lymphoma patients with rituximab and CHOP: A diagnostic and therapeutic challenge. Leukemia 2002;16:1884-1885. doi: 10.1038/ sj.leu.2402567.
7. Westhoff M, Jochimsen TH, Schmittel F, Stöfer-Meilicke A, Schäfer JH, Zidek W, et al. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003;102:1030. doi: 10.1182/blood-2003-05-1403.
8. Sarrecchia C, Cappelli A, Aiello P. HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAb. J Infect Chemother 2005;11:189-191. doi: 10.1007/s10156-005-0385-z.
9. Umemura T, Kiyosawa K. Fatal HBV reactivation in a subject with anti-HBs and anti-HBc. Intern Med 2006;45:747-748. doi: 10.2169/ internalmedicine.45.0158.
10. Rehermann B, Ferrari C, Pasquinelli C, Chizari FV. The hepatitis B virus persists for decades after patients' recovery from acute viral hepatitis despite active maintenance of cytotoxic T lymphocyte response. Nat Med 1996;10:1104-1108. doi: 10.1038/nm1096-1104.
11. Mason AL, Xu L, Guo L, Kuhns M, Perrillo RP. Molecular basis for persistent hepatitis B virus infection in the liver after clearance of serum hepatitis B surface antigen. Hepatology 1998;27:1736-1742. doi: 10.1002/hep-510270638.
12. Allain JP. Occult hepatitis B virus infection. Transfus Clin Biol 2004;11:18-25. doi: 10.1016/j.tracli.2003.11.007.
13. Sugauchi F, Orito E, Ichida T, Kato H, Sakugawa H, Kakumu D, et al. Epidemiologic and virologic characteristics of hepatitis B virus genotype B having the recombination with genotype C. Gastroenterology 2003;125:1916-1917. doi: 10.1053/j.gastro.2003.10.034.
14. Tadokoro K, Kobayashi M, Yamaguchi T, Suzuki F, Miyauchi S, Egashira T, et al. Classification of hepatitis B virus genotypes by the PCR-invader method with genotype-specific probes. J Virol Methods 2006;138:30-39. doi: 10.1016/j.jviromet.2006.07.014.
15. Wands JR, Chura CM, Roll FJ, Maddrey WC. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology 1975;68:105-112.
16. Kawatani T, Suou T, Tajima F, Ishiga K, Omura H, Endo A, et al. Incidence of hepatitis virus infection and severe liver dysfunction in patients receiving chemotherapy for hematologic malignancies. Eur J Haematol 2001;67:45-50. doi: 10.1034/j.1600-0609.2001.067001045.x.
17. Tsutsumi Y, Kawamura T, Saitoh S, Yamada M, Obara S, Miura T, et al. Hepatitis B virus reactivation in a case of non-Hodgkin's lymphoma treated with chemotherapy and rituximab: Necessity of prophylaxis for hepatitis B virus reactivation in rituximab therapy. Leuk Lymphoma 2004;45:627-629. doi: 10.1080/1042819031000151923.
18. Yeo W, Johnson PJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006;43:209-220. doi: 10.1002/hep-21051.
19. Hui CK, Cheung WWW, Zhang HY, Au WY, Yueng YH, Leung AYH, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 2006;131:59-68. doi: 10.1053/j.gastro.2006.04.015.
20. Lau GK, Yiu HHY, Fong DYT, Cheng HC, Au WY, Lai LSY, et al. Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 2003;125:1742-1749. doi: 10.1053/j.gastro.2003.09.026.
21. Chen AL, Hsiung CA, Su IJ, Chen PJ, Chang MC, Tsao CJ, et al. Lymphoma Committee of Taiwan Cooperative Oncology Group. Steroid-free chemotherapy decreases risk of hepatitis B virus (HBV) reactivation in HBV-carriers with lymphoma. Hepatology 2003;37:1320-1328. doi: 10.1053/ jhep.2003.50220.
22. Tur-Kaspa R, Burk RD, Shaul Y, Shafritz DA. Hepatitis B virus DNA contains a glucocorticoid-responsive element. Proc Natl Acad Sci USA 1986;83:1627-1631. doi: 10.1073/pnas.83.6.1627.
23. Persico M, Marino FD, Russo GDG, Severino A, Parmentieri B, Picardi M, et al. Efficacy of lamivudine to prevent hepatitis reactivation in hepatitis B virus-infected patients treated for non-Hodgkin lymphoma. Blood 2002;15:724-725. doi: 10.1182/blood.V99.2.724.
24. Shibolet O, Ilan Y, Gillis S, Hurbert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressive-induced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002;100:391-396. doi: 10.1182/blood.V100.2.391.
25. Rossi G. Prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HBsAg carriers with hemato-oncological neoplasias treated with chemotherapy. Leuk Lymphoma 2003;44:759-766. doi: 10.1080/ 104281903100006351.
26. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, et al. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000;119:172-180. doi: 10.1053/gast.2000.8559.
27. Dai MS, Chao TY, Kao WY, Shyu RY, Liu TM. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP. Ann Hematol 2004;83:769-774. doi: 10.1007/s00277-004-0899-y.
28. Kohrt HE, Ouyang DL, Keeffe EB. Antiviral prophylaxis for chemotherapy-induced reactivation of chronic hepatitis B virus infection. Clin Liver Dis 2007;4:965-991. doi: 10.1016/j.cld.2007.08.006.
29. Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol 2004;83:270-275. doi: 10.1007/s00277-003-0825-8.